Hansoh Pharmaceutical Group Company Limited (HNSPF)
- Previous Close
1.8800 - Open
1.8800 - Bid --
- Ask --
- Day's Range
1.8800 - 1.8800 - 52 Week Range
1.5000 - 1.8800 - Volume
100 - Avg. Volume
4 - Market Cap (intraday)
13.045B - Beta (5Y Monthly) 0.56
- PE Ratio (TTM)
26.86 - EPS (TTM)
0.0700 - Earnings Date --
- Forward Dividend & Yield 0.03 (1.45%)
- Ex-Dividend Date Jun 20, 2024
- 1y Target Est
--
Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical products in the People's Republic of China. The company provides products for therapeutic areas, including anti-tumor, anti-infectives, central nervous system diseases, metabolic diseases, and other therapeutic areas. Its principal products include Mailingda, Ameile, Hansoh Xinfu, Fulaimei, Hengmu, Xinwei, Tanneng, Ameining, Oulanning, Ailanning, Zetan, Ruibote, Fulaidi, Puruian, Fulairui, Pulaile, Zefei, Xinmei, Xintai, and Gainuo drugs, as well as XINYUE and Hengsen. The company serves pharmaceutical product distributors. It has a collaborations with NiKang Therapeutics to develop and commercialize NKT2152; TiumBio to develop and commercialize TU2670 for the treatment of endometriosis, uterine fibroids and other indications; Global Health Drug Discovery Institute to develop, manufacture, and commercialize the GDI-4405 series of anti-novel coronavirus; KiOmed Pharma SA to develop and commercialize KiOmedinevsOne for the treatment of osteoarthritis; and Biotheus Inc. to develop and commercialize PM1080. The company was founded in 1995 and is headquartered in Shanghai, the People's Republic of China. Hansoh Pharmaceutical Group Company Limited is a subsidiary of Stellar Infinity Company Ltd.
www.hspharm.com9,123
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: HNSPF
Performance Overview: HNSPF
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: HNSPF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: HNSPF
Valuation Measures
Market Cap
13.05B
Enterprise Value
10.21B
Trailing P/E
26.20
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
8.12
Price/Book (mrq)
3.13
Enterprise Value/Revenue
1.01
Enterprise Value/EBITDA
2.66
Financial Highlights
Profitability and Income Statement
Profit Margin
32.44%
Return on Assets (ttm)
5.31%
Return on Equity (ttm)
13.53%
Revenue (ttm)
10.1B
Net Income Avi to Common (ttm)
3.28B
Diluted EPS (ttm)
0.0700
Balance Sheet and Cash Flow
Total Cash (mrq)
24.86B
Total Debt/Equity (mrq)
16.69%
Levered Free Cash Flow (ttm)
--
Company Insights: HNSPF
HNSPF does not have Company Insights